Many cancer therapies function by activating proteins like Caspase-3 (CASP3) that promote cell death. Several forms of cancer develop resistance to these drugs by down regulating CASP3 through an unknown mechanism. In the absence of CASP3, tumor cells produce another cell death promoting protein CASP7, but it is rendered inactive by the X-linked inhibitor of apoptosis protein (XIAP). In this issue of the Journal of Clinical Investigation, Po-Huang Liang and colleagues at Academia Sinica identify a compound (I-Lys) that disrupts the interaction between CASP7 and XIAP. Release of CASP7 from this complex in drug resistant cancer cells activated cell death and reduced malignancies. Furthermore, no adverse side effects were observed in non-tumor cells treated with the drug. In the accompanying commentary, Gregory Gores from the Mayo Clinic explains that these results are promising for combatting drug resistant cancers, but more work needs to be done to establish if I-Lys will be safe and beneficial for human use.
TITLE: Targeting the XIAP/caspase-7 complex selectively kills caspase-3–deficient malignancies
Academia Sinica, Taiwan R.O.C., Taipei, , TWN
Phone: +886-2-3366-4069; E-mail: firstname.lastname@example.org
View this article at: http://www.jci.org/articles/view/67951?key=e86860a6dfda17980263
TITLE: Unshackling caspase-7 for cancer therapy
Gregory J Gores
Mayo Clinic, Rochester, MN, USA
Phone: 507-284-0686; Fax: 507-284-0762; E-mail: email@example.com
View this article at: http://www.jci.org/articles/view/71440?key=31dca5188081bce3f0ca
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.